熱門資訊> 正文

FDA接受ozeikibart的Inhibrx BLA

2026-06-15 22:34

Inhibrx Biosciences(INBX) 0
Crescent Biopharma(CBIO) 0

The US FDA has accepted for review Inhibrx Biosciences' (INBX) BLA for ozekibart to treat unresectable or metastatic conventional chondrosarcoma.
The application has an action date of April 14, 2027.
There are currently no FDA-approved therapies for the rare bone cancer.
The BLA is supported by data from the ChonDRAgon study that met its primary endpoint of a statistically significant median progression-free survival for individuals given ozekibart compared to placebo.
Ozekibart is considered a tetravalent death receptor 5 (DR5) agonist antibody.

More on Inhibrx Biosciences

Inhibrx: Spinoff Rumors Send Shares Soaring - Stunning Bull Run Can Continue
Inhibrx Biosciences FY25 Review: Catalyst-Driven Hold Ahead Of Key 2026 Data
Inhibrx Biosciences GAAP EPS of -$2.15
Inhibrx rises on upcoming interim mid-stage data for head and neck cancer asset
Seeking Alpha’s Quant Rating on Inhibrx Biosciences

推薦文章

風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。